Compare VHC & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | RNXT |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 42.4M |
| IPO Year | 2008 | 2021 |
| Metric | VHC | RNXT |
|---|---|---|
| Price | $13.26 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 13.6K | ★ 458.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.99 | ★ 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | $162,000.00 | ★ $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3140.00 | 2511.63 |
| 52 Week Low | $9.82 | $0.70 |
| 52 Week High | $29.00 | $1.51 |
| Indicator | VHC | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 62.45 |
| Support Level | N/A | $0.82 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 59.92 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. Its software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.